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Abstract
Background: It has been proposed that outer surface protein A (OspA) of Borrelia burgdorferi
sensu stricto contains a T helper 1 (Th1) cell epitope that could play a role in an autoimmune
response to hLFA1.
Methods: We used two peptides, hLFAL (aa326-345) and Borrelia burgdorferi OspAB31 (aa164-
183), as stimulating antigens to measure Th1 proinflammatory IFN cytokine production in
peripheral blood of Lyme disease patients presenting with EM without history of arthritis, as well
as in peripheral blood of healthy individuals.
Results: IFN responses to hLFA1 peptide were observed in 11 of 19 Lyme disease patients and
in 3 of 15 healthy controls. In contrast, only 2 of 19 of the Lyme disease patients and none of the
controls responded to the homologous OspAB31 peptide.
Conclusions: IFN was produced in response to stimulation with peptide hLFAL (aa326-345) in
peripheral blood of 58% of patients with early Lyme disease without signs of arthritis, as well as in
peripheral blood of 20% of healthy individuals, but not in response to stimulation with the
homologous OspAB31 (aa164-183) peptide (p < 0.05). Our results suggest that reactivity to the
hLFA1 peptide in peripheral blood may be the result of T cell degeneracy.
Background
Lyme disease is a multisystem disease caused by the spiro-
chete Borrelia burgdorferi [1,2]. Although most patients re-
spond to two to four weeks of antibiotic therapy, a few
individuals continue to have clinical manifestations after
treatment. These patients do not respond to additional
courses of antibiotics raising the possibility that a post in-
fectious immunologic process is responsible for these per-
sistent clinical manifestations.
T helper 1 responses are associated with antibiotic refrac-
tory Lyme disease [3,4]. Outer surface protein A (OspA)
from B. burgdorferi sensu stricto contains a helper T cell
epitope with a similar sequence to a segment in human
leukocyte function-associated antigen-1 (hLFA1). Gross et
al. found that individuals with treatment resistant Lyme
arthritis, but not other forms of arthritis, generated Th1-
IFN responses to OspA, hLFA1 and their highly related
peptide epitopes in synovial fluid. These authors pro-
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posed that cross-reactivity between an OspA epitope and
hLFA1, allows OspA primed T cells to remain activated by
continued stimulation through cells expressing hLFA1,
even after elimination of the spirochetes by antibiotic
therapy, initiating an autoimmune response to hLFA1 in
the joint [5,6]. Thus, the ongoing clinical manifestations
in refractory Lyme disease may not depend on persistent
infection, but to the immune response to a cross reactive
epitope in the etiological agent [7].
Since an autoimmune cross reactivity between B. burgdor-
feri OspA, human LFA1 and antibiotic resistant Lyme ar-
thritis has been suggested [6] and it is known that only a
subpopulation of Lyme arthritis patients are resistant to
treatment we wanted to further dissect the involvement of
OspA as well a possible reactivity to the hLFA1 peptide in
a population of early Lyme disease patients using healthy
individuals as controls. We used borrelia whole cell soni-
cate and the two peptides first identified by Gross et al.
[6], hLFAL (aa326-345) and OspAB31 (aa164-183) to
measure antigen-specific T cell reactivity in peripheral
blood of two groups, early Lyme disease patients without
history of arthritis and healthy individuals. Th1-IFN pro-
duction in response to the peptide hLFAL (aa326-345)
was more frequent than Th1 reactivity to the OspAB31
(aa164-183) peptide in peripheral blood of Lyme disease
patients presenting with erythema migrans as well as in a
subpopulation of healthy individuals.
Methods
Patients and controls
Samples were obtained from nineteen adult patients from
an endemic area enrolled in ongoing Lyme disease studies
at the Lyme Disease Center at the State University New
York at Stony Brook, NY and at New York Medical Col-
lege, Valhalla, NY. Sixteen of these patients presented with
early localized infection typified by the presence of well
defined erythema migrans (EM). They had no other signs
of disseminated infection. None of these patients devel-
oped Lyme arthritis. Seven patients were evaluated within
1 month of EM presentation (acute) and nine different pa-
tients at 3 months post EM presentation (convalescent).
Also, three patients presenting with Lyme disease symp-
toms (EM or arthralgia, mialgia) that had been previously
vaccinated with recombinant OspA were tested. All pa-
tients were treated with suitable antibiotics at the time of
diagnosis. We did not test antibiotic resistant Lyme arthri-
tis patients because we didn't have any in that category
during the course of the study. We don't see those patients
often in either Long Island or Westchester County, highly
endemic areas for Lyme disease. Twenty-one healthy
adults from the same endemic area, with no prior history
of Lyme disease and no prior serologic screening, were re-
cruited as controls. Whole blood samples were drawn
from each enrolled patient into a heparinized tube. The
blood was kept at room temperature and used within 24
h after it was obtained.
Antigens
Two synthetic, twenty amino acid peptides, B. burgdorferi
OspAB31 (aa164-183), GYVLEGTLTAEKTTLVVKEG and
hLFAL (aa326-345), acetyl-ELQKKIYVIEGTSKQDLTSF,
were custom contracted through the Small Scale Peptide
Synthesis laboratory at the HHMI Biopolymer / Keck
Foundation Biotechnology Resource Laboratory (Yale
University School of Medicine, CT). Suitably protected
peptide chains were constructed in an automated, step-
wise solid-phase protocol using FMOC N-protection for
N-alpha protection at each cycle. The peptides were all
synthesized on substituted benzhydrylamine-resins to
yield amidated C-termini. The amide group is a better ap-
proximation of peptide bonds than are free carboxyl ter-
mini.
Since T cell receptors recognize structures rather than ami-
no acid sequences and both peptides of 20 residues are
about 70% different we did not use an unrelated peptide
as control. Borrelia whole cell sonicate derived from B.
afzelii, strain Pko, was developed by CSL Biosciences (Mel-
bourne, Australia) in collaboration with CDC (Fort Col-
lins, Colorado, USA), as a stimulating antigen for the T
cell Lyme assay. This antigen was found to have a higher
stimulation rate in blood from Lyme disease patients than
that of B. burgdorferi sonicate used in [8]. This antigen was
kindly provided by Dr. Roland Martin (CSL Biosciences)
and was used as an internal control to check the perform-
ance of the assay.
T-Cell assay
We used the QuantiFERON®-CMI test (CSL Biosciences,
Melbourne, Australia). This assay allows detection of cy-
tokine production, which may occur in the absence of
proliferation. In persons exposed to B. burgdorferi, an ear-
ly, vigorous, and sustained specific T-cell response devel-
ops that precedes a measurable antibody response [9]. The
production of IFN 16–24 hours after antigen stimulation
is dependent on the presence of T-cells capable of rapid re-
sponse kinetics (antigen-primed effector and/or antigen-
primed memory population). These T-cell populations
are short lived and are strictly dependent on the presence
of antigen [10]. This assay is based on the release of gam-
ma-interferon (IFN) from sensitized lymphocytes during
a 16 to 24 hour incubation with antigens specific for the
pathogenic agent and subsequently quantification of IFN
levels by a single step ELISA. The ratio of IFN response to
antigen versus the response to negative control is quanti-
fied to determine if IFN production is due to prior expo-
sure. The assay is simple to perform and does not require
the isolation of lymphocytes [8]. Incorporation of the
positive control mitogen in the test allows for the detec-BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/25
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tion of immunocompromised individuals (eg. due to
AIDS) and thereby removes the risk of detection of false
negatives.
The test was carried out as instructed by the manufacturer.
A healthy individual is expected to have 0.8–1.2  106 Th
cells/ml of whole blood. First, heparinized whole blood
was aliquoted at 1 ml/per well (about 106 T helper cells/
ml) in a 24 well cell culture cluster (Costar) and stimulat-
ed with 120 l of the following antigens and controls:
sonicated borrelia or WCS at 2.5 g/ml, peptide hLFAL
(aa326-345) at 2.5 g/ml, peptide OspAB31 (aa164-183)
at 10 g/ml, mitogen (PHA) and negative (PBS) controls.
After overnight incubation (16–20 h) at 37C in a humid
chamber, the plasma was removed and the amount of
IFN was determined by a rapid single step ELISA provid-
ed with the test kit, as per protocol. The single step ELISA
was run against a standard curve of human IFN stand-
ards. The OD results from patient blood stimulated with
B. burgdorferi antigen (corrected for the saline control)
were converted into International Units per ml (IU/ml)
from a standard curve of the human IFN standards. The
IU/ml IFN values were used to calculate the % specific re-
sponse to the antigen for each sample. The % specific re-
sponse is the ratio of IFN response to test antigen (Ag)
minus negative control (N) versus the response to mi-
togen (M) minus negative control (N), times 100. We de-
termined the cutoff at 10% specific response.
Statistical analysis
The comparison between the response to OspAB31
(aa164-183) and hLFAL (aa326-345) was done using the
McNemar's exact test for correlated proportions [11] be-
cause the same population of patients was tested in a
paired-sample design. P values of < 0.05 were considered
statistically significant.
Results
Samples were obtained from nineteen (19) adult patients
and twenty-one (21) healthy adult individuals from en-
demic areas. The production of IFN in peripheral blood
stimulated with borrelia whole cell sonicate antigen
(WCS), hLFAL peptide (aa326-345) or OspAB31 (aa164-
183) peptide was evaluated. Sixteen of the nineteen pa-
tients presented with early localized infection typified by
the presence of well defined erythema migrans (EM). They
had no other signs of disseminated infection and did not
develop Lyme arthritis. Seven patients were evaluated
within 1 month of developing EM (acute) and nine other
patients were evaluated 3 months post EM presentation
(convalescent). The additional three patients tested were
OspA vaccine failures who presented with acute Lyme dis-
ease. These samples were not screened for anti-OspA anti-
bodies. The 21 healthy individuals samples were used as
controls.
The optimal concentration of antigen used in the assay
varies for each specific antigen. The concentration of the
WCS (2.5 g/ml or 2.5 g/~106 Th cells), was previously
determined at CSL Biosciences by dose response curve as
the optimal concentration of antigen to be used in this T
cell assay [8]. We used the peptide OspAB31 (aa164-183)
at 10 g/ml (or 10 g/~106 Th cells). This was the same
concentration of OspA peptide used in Gross et al. for 3 
105 Th cells [6]. The hLFA1 peptide was used at 2.5 g/ml
(or 2.5 g/~106 Th cells), the same concentration deter-
mined for the WCS. All antigens at the proposed concen-
trations were tested in blood from known healthy
individuals to determine the background level stimula-
tion.
To confirm the performance of the Th1-IFN assay, we
evaluated the results obtained with the borrelia whole cell
sonicate antigen (WCS) in both Lyme disease and healthy
individuals (Table 1). Of the 19 Lyme disease patients
studied, 5 acute, 4 convalescent and 3 infected OspA vac-
cinated patients (63%, 12/19) produced IFN when stim-
ulated with WCS. Of the 21 healthy individuals tested, 6
produced IFN when stimulated with WCS (29%). The
sensitivity of the assay obtained for the Lyme disease pa-
Table 1: IFN Specific Human Response (HR>10%) in LD Patients with EM and Healthy Individuals
N. of Patients Borrelia Whole Cell Sonicate N.Pos (%)
LD, EM, < 1 mo. 7 5 (71%)
LD, EM, 3 mo. 9 4 (44%)
LD, OspA Vaccinated 3 3 (100%)
LD total 19 12 (63%)
Healthy 21 6 (29%)
LD, Lyme disease; EM, erythema migrans; N.Pos., number of positivesBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/25
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tients was equivalent to data obtained independently with
the a borrelia whole cell sonicate stimulating antigen [8].
When we compared the Th1 reactivity between the two
peptides in the Lyme disease patients (Table 2) we found
that 58% (11/19) produced IFN when stimulated with
the hLFAL (aa326-345) and 11% (2/19) produced IFN
when stimulated with the OspAB31 (aa164-183) peptide
(p < 0.05, McNemar's exact test for correlated propor-
tions). There was no correlation between the IFN re-
sponse weather the patient was studied at less than one
month or three months post presentation (p > 0.05).
Twenty percent (3/15) of the healthy individuals that did
not react to borrelia WCS produced IFN when stimulated
with the hLFAL (aa326-345) and none (0/15) produced
IFN when stimulated with the OspAB31 (aa164-183)
peptide.
Observing the three vaccinated patients that came down
with Lyme disease, we verified they were all responsive
(100%) to the Borrelia WCS, 2/3 were positive for hLFA
peptide (67%) and none (0%) was positive for the OspA
peptide. This last result was surprising since these patients
had been previously vaccinated with OspA. However, this
could be explained by the obvious vaccine failure which is
supported by the fact that all three patients reacted with
borrelia whole cell sonicate.
Discussion
Our results show that the Th1 proinflamatory cytokine
IFN is produced in peripheral blood of patients with ear-
ly Lyme disease without any signs of arthritis when stim-
ulated with the peptide hLFAL(aa326-345) but not when
stimulated with the homologous OspAB31 (aa164-183)
peptide. This observation was also verified for healthy in-
dividuals.
It has been postulated that hLFA1 autoreactive T cells play
a major role in the pathogenesis of chronic Lyme arthritis
[6]. However, the hLFAL (aa326-345) peptide was not
recognized by any of the OspA (aa164-175)-specific T cell
hybridomas generated from a B. burgdorferi OspA immu-
nized DR4 transgenic mouse, illustrating that individual
T-cell receptor (TCR) possess different patterns of cross-re-
activity [12]. In addition, analysis at the clonal level dem-
onstrated that hLFAL (aa326-345) behaves as a partial
agonist for OspA-reactive T cells, not as a full agonist [13].
Antigen specificity of a single T-cell clone can be degener-
ate and yet the clone can preferentially recognize different
peptides derived from the same organism. This demon-
strates that flexibility in T cell recognition does not pre-
clude specificity. If recognition were not degenerate, the
immune system would be incompetent since the limited
number of T-cells in an organism would allow recognition
of small fraction of a mixture of randomized peptides
[14]. There is ample evidence suggesting that cross-reactiv-
ity leading to T cell activation is a very frequent event [15–
17,14,18,12]. In fact, the presence of cross-reactive T cells
is normal and required for the maintenance of memory T
cell responses. T cell reactivity between a microbial pep-
tide and a self-peptide alone is not sufficient to induce au-
toimmune disease [12].
TCR recognition of peptide-major histocompatibility
complex antigens can elicit a diverse array of effector activ-
ities. Itoh et al., analyzed TCR engagement and the pro-
duction of multiple cytokines in a clonal Th1 CD4+ cell
population. They verified that low concentrations of TCR
ligand elicit only IFN production. Their findings provide
strong support for a model of T cell activation in which
different effector functions have a hierarchical arrange-
ment of elicitation thresholds, such that the ratio of elicit-
ed effector molecules changes with antigen concentration
[19]. Rogers et al., used a model of differentiation that is
dependent on the initial dose and affinity of peptide pre-
sented to a naïve CD4 cell. They used this system to con-
firm that LFA 1 interaction can suppress differentiation of
cells secreting Th2 cytokines and that this interaction is
only seen over a range of peptide doses [20].
Table 2: IFN Specific Human Response (HR>10%) in LD Patients with EM and Healthy Individuals that were WCS Negative
Lyme Disease patients with EM N.Pos/total (%) Healthy, WCS neg 
N.Pos/total (%)
< 1 month At 3 months OspA vacc. LD total Healthy total
hLFAaL(aa326-345) 4/7 (57%) 5/9 (56%) 2/3 (67%) 11/19 (58%) 3/15 (20%)
OspAB31(aa164-183) 1/7 (14%) 1/9 (11%) 0/3 (0%) 2/19 (11%) 0/15 (0%)
WCS, whole cell sonicate; LD, Lyme disease; EM, erythema migrans; hLFA, human leucocyte associated function antigen; OspA vacc., OspA vacci-
nated; N.Pos., number of positivesBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/25
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We detected a Th1 response to hLFAL (aa326-345) in pe-
ripheral blood of patients with Lyme disease without any
signs of arthritis and in a subpopulation of healthy indi-
viduals. We observed that the reactivity to hLFA1 was sig-
nificant and was dissociated from the response to OspA.
The hLFA1 peptide was used at the same concentration
determined for the WCS and four times less the concentra-
tion used for the OspA peptide. We anticipated that differ-
ences in data obtained for a concentration of 25 g/ml for
the hLFA antigen compared to 10 ug/ml of the OspA anti-
gen as in Gross et al. [6] could cause skepticism. For that
reason, and to minimize the amount of variables in the
study, we chose a semi-empirical route.
Taking into account all previous findings, the greater re-
sponse to the hLFA peptide as compared to the OspA may
be explained by the different doses of hLFA peptide and
OspA used. An additional, and in our opinion better ex-
planation, is that reactivity to the hLFA1 peptide in pe-
ripheral blood is in large part the result of T cell
degeneracy. This could explain the number of healthy in-
dividuals who reacted to the hLFA1 peptide. An alterna-
tive to this model could be that some individuals may
have been infected with a previous pathogen that triggers
activation of T cells reactive to the hLFA1 peptide. In any
case, this does not rule out the possibility that primed hL-
FAL reactive Th1 cells homing to a specific milieu such as
the joint could potentially be involved in the pathogenic
mechanisms associated with chronic Lyme arthritis. Addi-
tional studies are required to define the role of T cell reac-
tivity in the immunopathogenesis of antibiotic refractory
Lyme disease.
Conclusions
We detected a significant Th1 response to the peptide hL-
FAL(aa326-345) in peripheral blood of patients with
early Lyme disease without any signs of arthritis and in a
subpopulation of healthy individuals. Our results suggest
that reactivity to hLFA1 peptide in peripheral blood may
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